The Commonwealth Serum Laboratories was established in Australia in 1916.
At CSL, Corporate Responsibility is about conducting our business ethically.
We offer the broadest range of quality plasma-derived and recombinant therapies in the industry.
Seqirus opened in 2015, born from the merging of CSL's bioCSL division and the Novartis influenza vaccine business.
Innovation has been in the DNA of CSL since our beginning in 1916
Our product portfolio focuses on innovation in new products
Our interim dividend for 2019 increased to US$0.85 per share, up 8%.
Our exceptionally strong performance is a result of the focused execution of our strategy.
Help us deliver on our promise to save lives and protect the health of people.
Make your well-being a priority. It's important and so are you.
View our ASX announcements
Visit this page to see all of our current news releases
CSL Limited have announced 2018 Full Year Results for the period ending 30 June 2018.
Full details including a link to the the streamed presentation can be viewed via the link below.
Popular search terms: